Catalent Aquires Relthy to Expand South American Business

Catalent Pharma Solutions has aquired Relthy Laboratórios in Brazil to expand its softgel technology business. The deal follows Catalent’s recent expansion into China, with softgel and clinical trial supply operations.

Catalent acquired 100% of the shares in the Indaiatuba-based, privately held company. Founded in 1988, Relthy produces softgel encapsulated vitamin, mineral and supplement (VMS) products for the Brazilian market, but also supplies products for the prescription and over-the-counter (OTC) segments. Relthy becomes Catalent’s 11th softgel facility adding to its existing pharmaceutical and OTC-focused South American facilities, located in Sorocaba, Brazil, and Buenos Aires, Argentina.

Relthy employs 350 staff and has annual production capacity of approximately 2 billion capsules per annum. The deal further expands Catalent's position into the VMS nutritional market while simultaneously expanding its primary and secondary packaging capabilities in the country. Relthy’s management team will join Catalent.